{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:26:38Z","timestamp":1790799998875,"version":"4.1.0"},"reference-count":24,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cerebrovasc Dis Extra"],"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; The use of the cardiovascular polypill, a fixed-dose combination treatment, is conceived to improve adherence. However, randomized controlled trials (RCTs) may overestimate it. Studies focusing on cerebrovascular disease and real-life efficacy compared with conventional treatment are lacking. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; This is a retrospective, hospital-based cohort study of acute ischaemic stroke patients who were prescribed a polypill (aspirin 100 mg, atorvastatin 20\/40 mg, ramipril 2.5\/5\/10 mg) versus conventional treatment (aspirin 100 mg and other blood pressure\/lipid-lowering agents) in secondary prevention (2017\u20132018). Clinical records were reviewed 90 days after discharge for stroke recurrence, vascular risk factor control, and safety. Adherence was assessed using the adapted Morisky-Green scale. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; A total of 104 patients were included (61% male; mean age 69.7 \u00b1 13.9 years); 54 were treated with the polypill and 50 with conventional treatment. No baseline differences in clinical or demographic variables were detected. No recurrences were registered in the polypill group, compared to 1 recurrence in the conventional treatment group. A significant reduction of systolic blood pressure (SBP) was achieved in the polypill group (12.1 mm Hg) compared to the conventional treatment group (6.8 mm Hg) (&lt;i&gt;p&lt;\/i&gt; = 0.002). No significant differences were detected regarding the goal of LDL cholesterol \u226470 mg\/dL (41 vs. 44%). The adverse events were mild and their frequency was similar in the two groups (9 vs. 2%, ns). Adherence was similarly good in the two groups (93 vs. 88%, ns). Polypill group adherence was similar to that reported in a previous meta-analysis of RCTs (93 vs. 84%, ns). &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; In our experience, the cardiovascular polypill achieved a higher reduction in SBP levels and was well tolerated. Adherence was similar to that found in the previous literature, which is remarkable given the real-life setting of our study. <\/jats:p>","DOI":"10.1159\/000511064","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T22:00:33Z","timestamp":1605132033000},"page":"166-173","source":"Crossref","is-referenced-by-count":13,"title":["Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients"],"prefix":"10.1159","volume":"10","author":[{"given":"Victoria","family":"Ros-Castell\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Natera-Villalba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"G\u00f3mez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantxa","family":"S\u00e1nchez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan\u00a0Luis","family":"Chico-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Garc\u00eda-Madrona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Vera-Lechuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Matute-Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"de\u00a0Felipe\u00a0Mimbrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cruz-Culebras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araceli","family":"Alonso-Canovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Masjuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2020,11,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000024"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.4949"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.recesp.2016.02.009"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.4936"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30553-6"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30558-5"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.08.021"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30695-5"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-017-0853-y"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/2047487314530382"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g3318"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.277064"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.12.015"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1185\/030079902125000787"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199312002-00006"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(15)31028-7"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2017.10.013"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2019.04.001"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.25.11.2220"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.24.1.35"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw106"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-36"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802712"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800410"}],"container-title":["Cerebrovascular Diseases Extra"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/511064","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/511064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:03:07Z","timestamp":1745424187000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000511064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,11]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,12,28]]}},"URL":"https:\/\/doi.org\/10.1159\/000511064","archive":["Portico"],"relation":{},"ISSN":["1664-5456"],"issn-type":[{"value":"1664-5456","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,11]]}}}